丁咯地尔治疗42例恢复期脑卒中病人

Buflomedil in treating 42 patients with stroke of convalescence period

目的 :观察丁咯地尔治疗恢复期脑卒中的临床疗效及安全性。方法 :82例住院的恢复期脑卒中病人在接受常规康复训练的基础上 ,随机分为丁咯地尔组 4 2例 ,给丁咯地尔 15 0～ 2 0 0mg ,对照组4 0例 ,给三七总皂苷 5 2 5～ 70 0mg ,均iv ,gtt ,qd×15d ,治疗结束后评价临床神经功能缺损 (NFD)程度、Fugl Meyer运动功能 (FMA)、日常生活活动能力Barthel指数 (BI)得分的变化及不良反应。结果 :丁咯地尔组、对照组的总有效率分别为 83% ,6 2 %(P <0 .0 5 )。治疗后NFD ,FMA ,BI评分分别为 (17±s 6 ) ,(6 6± 8) ,(79± 10 )分和 (2 0± 7) ,(46± 9) ,(5 8± 9)分 ,2组间比较 ,P <0 .0 1或P <0 .0 5 ;2组治疗前后NFD ,FMA ,BI评分比较 ,P <0 .0 1。 2组均未发现严重不良反应。结论 :丁咯地尔治疗恢复期脑卒中疗效肯定 ,不良反应少。

AIM: To observe the efficiency and safety of buflomedil in treating stroke patients of convalescence period. METHODS: Eighty-two inpatients with stroke of convalescence period and receiving rehabilitation were randomly divided into two groups: buflomedil group and control group. Both groups received regular rehabilitation therapy, besides, the buflomedil group (n=42) received buflomedil 150-200 mg, iv, gtt, qd, for 15 d and the control group (n=40) received Panax notoginseng saporins 525-700 mg, iv, gtt, qd for 15 d. After treatment, the change of scores of the neuro-function deficit score (NFD), Fugl-Meyer motor assessment (FMA), modified Barthel index (BI) and adverse reactions were evaluated for all patients in two groups respectively. RESULTS: The total effective rate of buflomedil group and control group was 83% and 62%,respectively, and the difference was significant (P<0.05). After treatment, the scores of NFD, FMA, BI in buflomedil group were (17±s 6), (66±8), (79±10),as those were (20±7), (46±9), (58±9) in control group, and the difference was significant between the two groups (P<0.01 or P< 0.05). There were significant differences between pre-treatment and post-treatment in scores of NFD, FMA, BI of two groups(P<0.01). Serious adverse reactions had not been found in both groups during the treatment. CONCLUSION: Buflomedil is effective and safe in treating stroke patients of convalescence period.